GlassScriptPhysician profile
Adam W Gedney
NPI 1326109018
$2,618.20
in general payments reported to CMS, 2019-2025
28 companies · $813 in 2025
The $813 reported for 2025 was more than what 80% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $232 · 2023: $759 · 2024: $814 · 2025: $813.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,386.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,385.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $337.34 | 2022-2025 | Farxiga, Airsupra, Breztri |
| Phathom Pharmaceuticals, INC. | $270.83 | 2024-2025 | Voquezna |
| Amgen INC. | $258.22 | 2022-2025 | Repatha, Krystexxa, Repatha |
| Novo Nordisk INC | $226.18 | 2022-2025 | Wegovy, Rybelsus, Ozempic |
| Glaxosmithkline, LLC. | $197.56 | 2023-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Abbvie INC. | $173.88 | 2023-2025 | |
| Dexcom, INC. | $145.57 | 2023-2025 | Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Abbott Laboratories | $111.83 | 2024-2025 | Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $90.36 | 2023-2024 | Verquvo, Belsomra |
| Sumitomo Pharma America, INC. | $74.62 | 2023-2024 | Gemtesa |
| Lilly USA, LLC | $72.30 | 2022-2025 | Jardiance, Mounjaro, Zepbound |
| Otsuka America Pharmaceutical, INC. | $68.34 | 2023-2025 | Rexulti |
| Forte Bio-Pharma LLC | $65.62 | 2022-2023 | Prolate, Nalocet |
| Astellas Pharma US INC | $65.10 | 2024 | Veozah |
| Radius Health, INC. | $53.66 | 2023-2024 | Tymlos |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $51.73 | 2024-2025 | Cologuard Collection Kit |
| Sunovion Pharmaceuticals INC. | $47.98 | 2022 | |
| Xeris Pharmaceuticals, INC. | $46.72 | 2023-2025 | Gvoke Hypopen |
| E.R. Squibb & Sons, L.L.C. | $42.47 | 2023-2024 | Eliquis |
| Nevro Corp. | $41.87 | 2023-2024 | Senza |
| Corium, LLC | $32.90 | 2023 | Adlarity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.88 | 2024-2025 | Jardiance |
| Ardelyx, INC. | $31.82 | 2024 | Ibsrela |
| Esperion Therapeutics, INC. | $23.40 | 2023 | Nexletol |
| Irhythm Technologies, INC. | $14.62 | 2024 | Zio Xt Patch, Zio Monitor |
| Janssen Pharmaceuticals, INC | $14.19 | 2022 | |
| Novartis Pharmaceuticals Corporation | $13.34 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $12.87 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adam Gedney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.